Report Publication Announcement • Apr 12, 2021
Report Publication Announcement
Open in ViewerOpens in native device viewer
12 April 2021
Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, [email protected].
This information is information that Immunicum is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on 12 April 2021.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting Chief Executive Officer Telephone: +31 713 322 627 E-mail: [email protected]
INVESTOR RELATIONS
Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: [email protected]
MEDIA RELATIONS
Eva Mulder and Sophia Hergenhan Trophic Communications Telephone: +49 175 222 57 56 E-mail: [email protected]
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, offthe-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.